76
|
Leng X, Leszczynski P, Jeka S, Liu S, Liu H, Miakisz M, Gu J, Kilasonia L, Stanislavchuk M, Yang X, Zhou Y, Dong Q, Mitroiu M, Addison J, Zeng X. POS0287 A PHASE III, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL TRIAL TO COMPARE BAT1806/BIIB800, A PROPOSED TOCILIZUMAB BIOSIMILAR, WITH TOCILIZUMAB REFERENCE PRODUCT IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE THERAPY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundBAT1806/BIIB800 is a proposed biosimilar to reference tocilizumab (TCZ). A Phase III randomised, double-blind, active-controlled clinical trial was conducted as part of a biosimilar development programme.ObjectivesTo evaluate the efficacy, pharmacokinetics (PK), safety and immunogenicity of BAT1806/BIIB800 in comparison with EU-sourced TCZ in subjects with moderate to severe rheumatoid arthritis with inadequate response to methotrexate (MTX).MethodsThe study was conducted at 55 centres in China and Europe, between June 2018 and January 2021. Eligible subjects were randomised in a 2:1:1 ratio to one of three treatment groups: (1) BAT1806/BIIB800 up to Week 48, (2) TCZ up to Week 48, or (3) TCZ up to Week 24, followed by BAT1806/BIIB800 from Week 24 to Week 48, administered intravenously every 4 weeks at a dose of 8mg/kg. The primary endpoint was the proportion of subjects achieving an ACR20 response at timepoints pre-specified to meet the requirements of different Regulatory Agencies: Week 12, for EMA; Week 24, for FDA and NMPA. Equivalence margins applied to differences in ACR20 response rates in the BAT1806/BIIB800 and TCZ treatment groups were pre-specified as follows: +/- 14.5% for EMA (95% confidence interval (CI)); -12.0%,15% for FDA (90% CI); +/- 13.6% for NMPA (95% CI). Secondary endpoints included pharmacokinetics, safety and immunogenicity.The ICH E9(R1) estimands framework including intercurrent events (related or unrelated to the COVID19 pandemic) was implemented for the ACR20 evaluation. A logistic regression model including ‘region’ (China and Eastern Europe) and ‘previous biologic or targeted synthetic DMARD use’ (Yes/No) as captured in Interactive Web Response System as stratification factors was utilised to assess equivalence for the primary endpoint. The difference in response rates was estimated and corresponding confidence intervals were derived to assess equivalence for the primary endpoint. This abstract presents results up to Week 24.ResultsIn total, 621 subjects were randomised to receive BAT1806/BIIB800 (N=312), TCZ (N=155), or TCZ followed by BAT1806/BIIB800 (N=154). The groups were comparable in terms of baseline demographics and disease characteristics, including age, gender, disease activity and disease duration. The estimated proportions of subjects achieving an ACR20 response in the BAT1806/BIIB800 vs. the TCZ groups, respectively, were 68.97% vs. 64.82% at Week 12 and 69.89% vs. 67.94% at Week 24. The estimated difference between ACR response rates was 4.15% (95% CI -3.63, 11.93) at week 12, and 1.94% (90% CI -4.04, 7.92; 95% CI -5.18, 9.07) at Week 24. The CIs for the estimated differences between the treatment groups were within the pre-defined equivalence margins (Figure 1). The treatment groups were comparable in terms of serum trough levels, incidence of TEAEs and ADA/NAb positivity (Table 1).Table 1.Safety and Immunogenicity up to Week 24, and Pharmacokinetics at Week 24TCZ (N =309) n (%)BAT1806/BIIB800 (N=312) n (%)TEAE196 (63.4)201 (64.4)Related TEAE151 (48.9)148 (47.4)Serious TEAE13 (4.2)11 (3.5)Related Serious TEAE7 (2.3)2 (0.6)Fatal TEAE1 (0.3)3 (1.0)ADA positive a42 (13.6%)64 (20.5%)NAb positive a42 (13.6%)63 (20.2%)PK, n271276Serum trough level (ug/mL), mean (SD)15.4 (17.1)15.8 (12.3)Serum trough level (ug/mL), geometric mean (CV%)12.3 (140.3)12.9 (121.3)Below limit of quantification, n (%)43 (15.9)28 (10.1)TEAE, treatment emergent adverse eventsa subjects with ≥1 ADA/NAb positive results up to week 24ConclusionBAT1806/BIIB800 has demonstrated equivalent efficacy at Week 12 and Week 24 and a similar PK, safety and immunogenicity profile as reference tocilizumab up to Week 24.Disclosure of InterestsXiaomei Leng: None declared, Piotr Leszczynski: None declared, Sławomir Jeka: None declared, Shengyun Liu: None declared, Huaxiang Liu: None declared, Malgorzata Miakisz: None declared, Jieruo Gu: None declared, Lali Kilasonia Speakers bureau: Sandoz, Amgen, Takeda, Mykola Stanislavchuk Speakers bureau: Pfizer, Orion, Boehringer Ingelheim, Xiaolei Yang Shareholder of: Employee of the Bio-thera Solutions Ltd. with shares as a part of Stock incentive plan., Employee of: Employee of the Bio-thera Solutions Ltd., Yinbo Zhou Shareholder of: Employee of Bio-thera Solutions Ltd. with share as part of Stock incentive plan, Employee of: Employee of Bio-thera Solutions Ltd., Qingfeng Dong Shareholder of: Employee of Bio-thera Solutions Ltd. with shares as part of Stock incentive plan, Employee of: Employee of Bio-thera Solutions Ltd., Marian Mitroiu Shareholder of: Employee of Biogen and may hold stocks, Employee of: Employee of Biogen, Janet Addison Shareholder of: Employee of Biogen and holds stock in Biogen, Employee of: Employee of Biogen, Xiaofeng Zeng: None declared
Collapse
|
77
|
Dong X, Shi Y, Xia Y, Zhang X, Qian J, Zhao JL, Peng J, Wang Q, Weng L, LI M, Du B, Zeng X. POS1368 DIVERSITY OF HEMODYNAMIC TYPES IN CONNECTIVE TISSUE DISEASE ASSOCIATED PULMONARY HYPERTENSION: MORE THAN A SUBGROUP OF PULMONARY ARTERIAL HYPERTENSION. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundConnective tissue disease (CTD) associated pulmonary hypertension (PH) is classified as a subgroup of WHO group 1 PH, also called pulmonary arterial hypertension (PAH). However, not all CTD-PH fit the hemodynamic definition of PAH. This study investigates the diversity of hemodynamical types of CTD-PH, their different clinical characteristics and outcomes.ObjectivesThis study investigates the diversity of hemodynamical types of CTD-PH, their different clinical characteristics and outcomes.MethodsWe performed a retrospective cohort study. CTD-PH patients underwent right heart catheterization (RHC) were enrolled and divided into WHO group1 PH, WHO group 2 PH and high output PH (PVR<3WU and PAWP<15mmHg) according to hemodynamic features. Patients with obvious lung diseases, left heart disease and pulmonary embolism were excluded. Baseline characteristics, inflammatory markers, autoantibodies, cardiac function status, echocardiogram parameters, hemodynamics and survival rates were compared.Results207 CTD-PH patients were included, including 139 in WHO group 1 PH, 36 in WHO group 2 PH and 32 in high output PH. Incidence of anti-ribonucleoprotein antibody was lower in WHO Group 2 PH. High output PH is less severe, presenting lower NT-proBNP level, better WHO functional class, lower mPAP and PVR, higher cardiac output, and less cardiac remodeling. Among patients with elevated PAWP, combine pre& post-capillary PH had higher mPAP and larger right ventricle diameter. Association of mild to moderate interstitial lung disease didn’t show significant difference in disease characteristics. Short-term survival was significantly worse in WHO group 2 PH, yet 5-year survival rates didn’t differ between groups.ConclusionPre-capillary PH is not the only hemodynamic type of CTD-PH. Different types of CTD-PH present different clinical phenotypes and outcome. Carefully phenotyping PH in CTD-PH patients is important.Disclosure of InterestsNone declared
Collapse
|
78
|
Shi Y, Zhao J, Zeng X. AB0542 ANTIPHOSPHOLIPID ANTIBODY CARRIERS WITH THROMBOCYTOPENIA COULD BE AN INDEPENDENT PHENOTYPE OF PRIMARY ANTIPHOSPHOLIPID SYNDROME. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundAmong patients with immune thrombocytopenic (ITP), 10-20% of them were found with positive antiphospholipid antibodies (aPLs) but without typical clinical manifestations of antiphospholipid syndrome (APS), especially thrombotic events1.ObjectivesTo compare the clinical characteristics and prognosis between aPLs carriers and patients with APS.MethodsThis is a single center prospective cohort study consecutively enrolling thrombocytopenic patients with continuous positive aPLs. Patients developing thrombotic events are classified as the APS group. The exclusion criteria are other underlying connective tissue diseases such as lupus and other causes that might manifest as thrombocytopenia, such as virus infection, hypersplenism, etc.ResultsThis cohort included 47 thrombocytopenic patients with continuous positive aPLs and 55 with diagnosed primary APS. The proportion of thrombotic high risk demographic characteristics including smoking, hypertension, and higher level of homocysteine are higher in the APS group (p = 0.03, 0.04, 0.03, respectively). The prevalence of nephropathy was significantly higher in patients with diagnosed APS [0 vs 7 (12.7%), p =0.01]. Laboratory results and antibody profiles are presented in Table 1. The platelet count of aPLs carriers at admission was lower than APS patients [26×109/L (9×109/L, 46×109/L) vs 64×109/L (24×109/L, 89×109/L), p = 0.0002]. The proportion of positive anti-β2-glycoprotein I, anticardiolipin and lupus anticoagulant separately was similar, but triple aPLs positivity is more common in primary APS patients with thrombocytopenia [24 (51.1%) vs 40 (72.7%), p = 0.04]. There is no significant differences over the complement levels between the two groups [p = 0.2 for low complement 3 (C3), p = 0.8 for low C4]. Regarding the treatment response, the complete response (CR) rate is similar between aPLs carriers and primary APS patients with thrombocytopenia (p = 0.2). Nonetheless, the proportion of response, no response and relapse differed significantly between the two groups [13 (27.7%) vs 4 (7.3%), p < 0.0001; 5 (10.6%) vs 8 (14.5%), p < 0.0001; 5 (10.6%) vs 8 (14.5%), p < 0.0001, respectively]. In Kaplan-Meier analysis (Figure 1), primary APS patients had significantly more thrombotic events than aPLs carriers (p = 0.0006). aPLs carriers with thrombocytopenia share similar clinical manifestations with primary APS patients but hardly develop thrombotic events.Figure 1.Kaplan-Meier analysis of thrombotic events.aPLs: antiphospholipid antibodies; PAPS: primary antiphospholipid syndrome.Table 1.Baseline characteristics of laboratory results and antibody profiles.CharacteristicsaPLs carriers (n=47)Primary APS with thrombocytopenia (n=55)p-valueLaboratory results, median (Q1, Q3)Platelet count (×109/L)26 (9,46)64 (24, 89)0.0002*hsCRP (mg/L)1.39 (0.475, 2.845)1.08(0.41, 2.565)0.8ESR (mm/h)5.5 (2.75, 10.75)7.5 (5, 14.25)0.06LDH (U/L)221 (176, 252)228 (184.8, 282)0.3Low C3, n (%)3 (6.4)9 (16.4)0.2Low C4, n (%)5 (10.6)8 (14.5)0.8Antibody profiles, n (%)Positive aCL45 (95.7)33 (69.1)0.3Positive Anti-β2GP I38 (80.9)48 (87.3)0.5Positive LA35 (74.5)50 (90.9)0.05Triple positivity24 (51.1)40 (72.7)0.04*Positive Coombs,6 (12.8)10 (18.2)0.4*p < 0.05, statistically significant. aPLs: antiphospholipid antibodies; APS: antisphopholipid syndrome; Q1/3: quantile 1/3; hsCRP: hypersensitive C-reactive protein; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase; C3/4: complement 3/4; aCL: anticardiolipin; GP: glycoprotein; LA: lupus anticoagulant.ConclusionIn the absence of other high risk factor for thrombosis, Thrombocytopenia could be an independent and long-lasting clinical phenotype for aPLs carriers.References[1]Bidot CJ, Jy W, Horstman LL, Ahn ER, Yaniz M, Ahn YS. Antiphospholipid antibodies (APLA) in immune thrombocytopenic purpura (ITP) and antiphospholipid syndrome (APS). Am J Hematol. Jun 2006;81(6):391-6.Disclosure of InterestsNone declared
Collapse
|
79
|
Van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman R, Kameda H, Zeng X, Sui Y, Bu X, Pangan A, Wung P, Song IH. POS0306 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2518] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundUpadacitinib (UPA) was shown to be safe and effective through 2 years in patients (pts) with active ankylosing spondylitis (AS) naïve to biologic disease-modifying antirheumatic drugs (bDMARDs) in the pivotal phase 2/3 SELECT-AXIS 1 trial.1,2ObjectivesTo assess the efficacy and safety of UPA in pts with active AS with an inadequate response (IR) to bDMARDs.MethodsSELECT-AXIS 2 (NCT04169373) was conducted under a master protocol and includes two separate studies (one for AS bDMARD-IR and one for non-radiographic axial spondyloarthritis [nr-axSpA]). The AS bDMARD-IR study is a randomized, double-blind, placebo (PBO)-controlled, phase 3 trial that enrolled adults ≥18 years with AS who met modified New York criteria, had BASDAI and pt’s assessment of total back pain scores ≥4 (numeric rating scale 0–10) at study entry, and had an IR to one or two bDMARDs (TNF inhibitor or IL-17 inhibitor). Pts were randomized 1:1 to receive oral UPA 15 mg once daily (QD) or PBO during the 14-week (wk) double-blind treatment period. The primary endpoint was ASAS40 response at wk 14. Multiplicity-controlled secondary endpoints evaluated at wk 14 were improvements from baseline in disease activity (ASDAS [CRP], ASDAS ID [<1.3], ASDAS LDA [<2.1], BASDAI50, ASAS20, and ASAS PR), pain (total and nocturnal back pain), function (BASFI), objective measure of inflammation (SPARCC MRI score of the spine), spinal mobility (BASMI), enthesitis (MASES), and quality of life (ASQoL and ASAS HI). Non-responder imputation incorporating multiple imputation (NRI-MI) was used to handle intercurrent events and missing data for binary endpoints. Cochran-Mantel-Haenszel (CMH) test and mixed-effect model for repeated measures (MMRM) were used for analyzing binary and continuous endpoints, respectively. Treatment-emergent adverse events (TEAEs) assessed through wk 14 are reported for pts who had ≥1 dose of study drug.ResultsAll 420 randomized pts with active AS received assigned treatment (UPA 15 mg, n=211; PBO, n=209); 409 (97%) received study drug through wk 14. Baseline demographic and disease characteristics were generally similar between treatment groups and reflective of an active AS bDMARD-IR population (74% male; mean age 42.4 years; mean disease duration 7.7 years; 83% HLA-B27 positive; mean BASDAI 6.8). Significantly more pts achieved the primary endpoint of ASAS40 response at wk 14 with UPA vs PBO (45% vs 18%; P<0.0001; Figure 1); UPA showed onset of effect in ASAS40 as early as wk 4 (nominal P≤0.05). All multiplicity-controlled secondary endpoints met statistical significance for UPA vs PBO at wk 14 across multiple clinical domains of AS (P<0.0001; Figure 1). The rate of TEAEs was similar between treatment groups through wk 14 (UPA, 41%; PBO, 37%). TEAEs led to discontinuation in 3 (1.4%) pts treated with PBO and none with UPA. Serious infections occurred with UPA (2.4%) but not with PBO and included 4 events of COVID-19 and 1 event of uveitis. Additional events of uveitis were reported in 3 (1.4%) pts treated with PBO. Inflammatory bowel disease (IBD) occurred in 1 (0.5%) pt on UPA and none on PBO. No malignancy, major adverse cardiovascular events, venous thromboembolic events, or death were reported with UPA; 1 event of malignancy was observed with PBO.ConclusionUPA 15 mg QD was significantly more effective than PBO over 14 wks of treatment in pts with active AS and IR to bDMARDs. No new safety risks were identified with UPA compared with its known safety profile.3,4 These findings are consistent with and complementary to those of SELECT-AXIS 1 (bDMARD-naïve AS population),1,2 and support the use of UPA in pts with active AS, including those who had a previous IR to bDMARD therapy.References[1]van der Heijde D, et al. Arthritis Rheumatol. 2021;73(suppl 10).[2]van der Heijde D, et al. Lancet. 2019;394(10214):2108–2117.[3]Cohen SB, et al. ARD. 2021;80:304–311.[4]Burmester G, et al. Rheumatol Ther. 2021;1–19.AcknowledgementsAbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, review, and approval of the abstract. No honoraria or payments were made for authorship. Medical writing support was provided by Julia Zolotarjova, MSc, MWC, of AbbVie.Disclosure of InterestsDésirée van der Heijde Consultant of: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, and UCB, Employee of: Director of Imaging Rheumatology BV, Xenofon Baraliakos Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB, and Werfen, Grant/research support from: AbbVie, Novartis, Joachim Sieper Speakers bureau: AbbVie, Janssen, Merck, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Merck, and Pfizer, Atul Deodhar Consultant of: AbbVie, Amgen, Aurinia, BMS, Celgene, GSK, Janssen, Lilly, MoonLake, Novartis, Pfizer, and UCB., Grant/research support from: AbbVie, GSK, Lilly, Novartis, Pfizer, and UCB, Robert Inman Consultant of: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and Sandoz, Grant/research support from: AbbVie, Amgen, and Janssen, Hideto Kameda Speakers bureau: AbbVie, Asahi-Kasei, BMS, Chugai, Eisai, Janssen, Lilly, Mitsubishi-Tanabe, Novartis, and Pfizer, Consultant of: AbbVie, Janssen, Lilly, Novartis, Sanofi, and UCB, Grant/research support from: AbbVie, Asahi-Kasei, Boehringer Ingelheim, Chugai, Eisai, and Mitsubishi-Tanabe, Xiaofeng Zeng: None declared, Yunxia Sui Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, Xianwei Bu Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, Aileen Pangan Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, Peter Wung Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, In-Ho Song Shareholder of: May own AbbVie stock or options, Employee of: AbbVie
Collapse
|
80
|
Zeng X, Jiang H, Yang G, Ou Y, Lu S, Jiang J, Lei R, Su L. Regulation and management of the biosecurity for synthetic biology. Synth Syst Biotechnol 2022; 7:784-790. [PMID: 35387231 PMCID: PMC8958255 DOI: 10.1016/j.synbio.2022.03.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 03/11/2022] [Accepted: 03/17/2022] [Indexed: 11/26/2022] Open
Abstract
Synthetic biology (SynBio) is a high-profile interdiscipline combining engineering with science. As a dual-purpose discipline, SynBio is bringing large changes to many fields and providing great benefits to humans. However, due to its characteristic of complexity and uncertainty, SynBio also presents potential biosafety and biosecurity risks. Biosecurity risks refer to unauthorized access, loss, theft, misuse, diversion or intentional release. If a biosecurity accident happens, it would pose a huge threat to humans and nature. Therefore, it is crucial to establish a set of regulations and management practices for the biosecurity risks of SynBio. In this paper, we summarized the sources of the biosecurity risks of SynBio, from its research materials, products, technologies, information to Do-it-yourself synthetic biology. We reviewed and analyzed the current situation of regulation and management of biosecurity for SynBio in the international community and in China. We found that in most countries and regions, SynBio risks commonly follow the regulation and management of Genetically Modified Organisms which has loopholes if applied to the regulation for SynBio without any amendments. Here, we proposed suggestions for the Chinese-featured regulation and management of biosecurity for SynBio, including a top-to-bottom governing framework, a think-tank implementation mechanism, a Synthetic Biology Laboratory Biosecurity Manual safeguarding system, and strengthening biosecurity education on synthetic biology and self-regulation awareness among relevant personnel. Through this work, we aim to improve the standardized process of biosecurity regulation and management for SynBio in China and thereby map out a peaceful, profitable, and practical development path for synthetic biology.
Collapse
|
81
|
Kay J, Zeng X, Chen L, Tang K, Shi G, Liu L, Wu L, Liu Y, Hu J, Liu S, Yi Z, Kim SH, Bae Y, Suh J, Rhee S, Lee S, Hwang C. AB0339 EFFICACY, PHARMACOKINETICS AND SAFETY BETWEEN CT-P13 AND CHINA-APPROVED INFLIXIMAB: 54 WEEK RESULT FROM A PHASE III RANDOMIZED CONTROLLED TRIAL IN CHINESE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundCT-P13 is an approved biosimilar to EU-approved and US-licensed Infliximab (INX) for the indications of rheumatoid arthritis (RA), adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.ObjectivesThe purpose of this study was to demonstrate equivalence of efficacy and compare PK and safety profiles of CT-P13 and China-approved INX.MethodsIn this randomized, double blinded, multicenter, parallel-group, phase III study, patients with active RA who had been responding inadequately to methotrexate for at least 3 months, were randomized to receive either CT-P13 or China-approved INX. Patients were treated with doses of 3 mg/kg at Weeks 0, 2, 6, then every 8 weeks up to Week 54. Prior to dosing at Week 30, patients randomized to China-approved INX underwent a second randomization either to continue China-approved INX or to switch to CT-P13 at Week 30. Results of patients who underwent transition to CT-P13 were included in the China-approved INX group. The primary efficacy endpoint was change in DAS28 (CRP) from baseline to Week 14, which was analyzed using an analysis of covariance. Equivalence was determined if the 90% CI for the estimate of treatment difference was entirely contained within the predefined equivalence margin of -0.6 to 0.6.Results270 patients were randomly assigned to 2 treatment groups in a 1:1 ratio (136 and 134 patients in the CT-P13 and China-approved INX groups, respectively) and 184 patients completed the study. The least square mean change (standard error) of DAS28 (CRP) from baseline to Week 14, -1.566 [0.1419] and -1.547 [0.1491], was similar between the CT-P13 and China-approved INX groups, respectively. The 90% CI for the estimate of treatment difference (-0.29, 0.25) was contained within the predefined equivalence margin, which demonstrated therapeutic equivalence between the groups. The mean actual values for DAS28 (CRP) decreased from baseline to Week 54 and were similar between the groups (Figure 1). Additional efficacy endpoints, including ACR responses (ACR20 at Week 14; 60.6%, 54.8% and at Week 54; 65.1%, 60.6% in the CT-P13 and China-approved INX groups, respectively), EULAR responses, CDAI, and SDAI, were similar between the groups, even after switching at Week 30. During the study, mean serum INX concentrations were similar between the groups. Between Weeks 14 and 22, mean (percent coefficient of variation) AUCτ were 11156333.615 (44.796) ng·h/mL and 11462884.280 (51.057) ng·h/mL, and Cmax,ss were 66577.2 (31.4) ng/mL and 66356.1 (21.0) ng/mL in the CT-P13 and China-approved INX groups, respectively, which were similar between the groups. Most treatment-emergent AEs were grade 1 or 2 in intensity. One malignancy was reported in the CT-P13 group and no deaths were reported. The proportions of patients with anti-drug antibodies were similar between the groups, even after switching at Week 30. The overall safety profile of CT-P13 was comparable to that of China-approved INX and no new safety issues were observed (Table 1).Table 1.Summary of Safety ResultsNumber of patients (%)CT-P13 (N=136)China-approved Infliximab (N=133)Treatment-emergent AEsTotal115 (84.6%)107 (80.5%)Related97 (71.3%)86 (64.7%)Treatment-emergent serious AEsTotal17 (12.5%)12 (9.0%)Related10 (7.4%)6 (4.5%)Infusion related reaction/ hypersensitivity/anaphylactic reactionsTotal(=Related)20 (14.7%)19 (14.3%)InfectionsTotal45 (33.1%)43 (32.3%)Related36 (26.5%)40 (30.1%)Note: Summary is presented for the safety population who received at least 1 dose (full or partial) of study drug.ConclusionThe study demonstrated that efficacy of CT-P13 is equivalent to that of China-approved INX. Also, the PK and safety profiles of CT-P13 were comparable to those of China-approved INX. No loss of efficacy or difference in safety or immunogenicity was observed after switching from China-approved INX to CT-P13 at Week 30.Disclosure of InterestsJonathan Kay Consultant of: Boehringer Ingelheim GmbH; Pfizer Inc.; Samsung Bioepis; Sandoz Inc., Grant/research support from: Pfizer Inc. (paid to UMass Chan Medical School), Xiaofeng Zeng Grant/research support from: Celltrion, Inc, Lin Chen Grant/research support from: Celltrion, Inc, Kaijiang Tang Grant/research support from: Celltrion, Inc, guixiu shi Grant/research support from: Celltrion, Inc, Lin Liu Grant/research support from: Celltrion, Inc, Lijun Wu Grant/research support from: Celltrion, Inc, Yi Liu Grant/research support from: Celltrion, Inc, Jiankang Hu Grant/research support from: Celltrion, Inc, Shengyun Liu Grant/research support from: Celltrion, Inc, Zheng Yi Grant/research support from: Celltrion, Inc, Sung Hyun Kim Employee of: Celltrion, Inc, YunJu Bae Employee of: Celltrion, Inc, JeeHye Suh Employee of: Celltrion, Inc, Seungjin Rhee Employee of: Celltrion, Inc, SeulGi Lee Employee of: Celltrion, Inc, Chankyoung Hwang Employee of: Celltrion, Inc
Collapse
|
82
|
Yang G, Lu S, Jiang J, Weng J, Zeng X. Kub3 Deficiency Causes Aberrant Late Embryonic Lung Development in Mice by the FGF Signaling Pathway. Int J Mol Sci 2022; 23:ijms23116014. [PMID: 35682694 PMCID: PMC9181541 DOI: 10.3390/ijms23116014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2022] [Revised: 05/16/2022] [Accepted: 05/24/2022] [Indexed: 02/04/2023] Open
Abstract
As a Ku70-binding protein of the KUB family, Kub3 has previously been reported to play a role in DNA double-strand break repair in human glioblastoma cells in glioblastoma patients. However, the physiological roles of Kub3 in normal mammalian cells remain unknown. In the present study, we generated Kub3 gene knockout mice and revealed that knockout (KO) mice died as embryos after E18.5 or as newborns immediately after birth. Compared with the lungs of wild-type (WT) mice, Kub3 KO lungs displayed abnormal lung morphogenesis and pulmonary atelectasis at E18.5. No difference in cell proliferation or cell apoptosis was detected between KO lungs and WT lungs. However, the differentiation of alveolar epithelial cells and the maturation of type II epithelial cells were impaired in KO lungs at E18.5. Further characterization displayed that Kub3 deficiency caused an abnormal FGF signaling pathway at E18.5. Taking all the data together, we revealed that Kub3 deletion leads to abnormal late lung development in mice, resulting from the aberrant differentiation of alveolar epithelial cells and the immaturation of type II epithelial cells due to the disturbed FGF signaling pathway. Therefore, this study has uncovered an essential role of Kub3 in the prenatal lung development of mice which advances our knowledge of regulatory factors in embryonic lung development and provides new concepts for exploring the mechanisms of disease related to perinatal lung development.
Collapse
|
83
|
Zhao Y, Huang C, Qi W, Zhao J, Li M, Zeng X. OP0145 VALIDATION OF 3 PREDICTION MODELS FOR THROMBOSIS IN ANTIPHOSPHOLIPID SYNDROME PATIENTS BASED ON A PROSPECTIVE COHORT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundAntiphospholipid syndrome (APS) is a rare and complicated acquired autoimmune thrombophilia characterized by arterial/venous thrombosis and/or recurrent pregnancy loss. Thrombosis is the first cause of death of APS patients. However, there has been no generally acknowledged model to predict thrombosis. Only adjusted global APS score (aGAPSS) was developed for prediction but based on a cross-sectional study1. Additionally, the predictive ability of Padua score and Caprini score has not been validated in APS patients.ObjectivesAim to validate the ability of aGAPSS, Padua score and Caprini score to predict thrombosis in APS patients basing on a prospective cohort.MethodsConsecutive APS patients who fulfilled the 2006 Sydney Revised Classification Criteria for APS, referred to Peking Union Medical College Hospital were included. Clinical data, aGAPSS, Padua score, and Caprini score at the time of diagnosis were collected. Patients with less than 1-year follow-up were excluded. Harrell c-index and calibration curve were used to validate the prediction models.ResultsA total of 302 patients were enrolled in this study. The mean age was 32±12 years old, and 202 (66.9%) were female (Table 1). Patients were followed up for a median of 36 months. During the follow-up period, there were 62 thrombotic events, with 40 (13.25%) venous and 22 (7.28%) arterial thrombosis. The 1-, 3-, and 5-year thrombosis risks were 8.9%, 16.9%, and 21.3% respectively (Figure 1A). The Harrell c-indexes for predicting thrombosis of aGAPSS, Padua score, and Caprini score were 0.56 (95% confidence interval [CI], 0.52-0.60), 0.58 (95% CI, 0.54-0.62), and 0.61 (95%CI, 0.57-0.65) respectively. The model predicting venous thrombosis with the best discrimination was Padua score whose Harrell c-index was 0.64 (95% CI, 0.60-0.68), and the model predicting arterial thrombosis with the best discrimination was Caprini score whose Harrell c-index was 0.62 (95%CI, 0.56-0.68). The calibration curves illustrated that the calibration for predicting thrombosis within 3 years after diagnosis of all the 3 models was poor (Figure 1B-D).Table 1.Demographic characteristics and clinical manifestations at baselineN=302N=302Age, mean±SD32±12Clinical manifestationsFemale, n (%)202 (66.9)Venous thrombosis, n (%)156 (51.7)Disease duration (months), median (Q1, Q3)11.50 (3.00, 44.00)Deep venous thrombosis, n (%)112 (37.1)Secondary to SLE, n (%)73 (24.2)Pulmonary embolism, n (%)70 (23.2)Smoking history, n (%)63 (20.9)Visceral venous thrombosis, n (%)12 (4.0)Hypertension, n (%)59 (19.5)Cranial venous sinus thrombosis, n (%)13 (4.3)Hyperlipidemia, n (%)151 (50.0)Arterial thrombosis, n (%)113 (37.4)BMI, mean±SD23.96±3.89Stroke/TIA, n (%)62 (20.5)LA positive, n (%)241 (79.8)Myocardial infarction, n (%)14 (4.6)aCL positive, n (%)208 (68.9)Arterial thrombosis of lower extremities, n (%)22 (7.3)aβ2GPI positive, n (%)242 (80.1)Visceral arterial thrombosis, n (%)18 (6.0)Triple aPL positive, n (%)165 (54.6)Thrombocytopenia, n (%)118 (39.1)Obstetric manifestations, n (%)N=202Valvular lesions, n (%)24 (7.9)Pregnancy morbidity103 (51.0)Early miscarriages (<10 weeks)13 (6.4)Fetal death (>= 10 weeks)68 (33.7)Preeclampsia, eclampsia and placental dysfunction36 (17.8)Figure 1.The Kaplan-Meier curve and the calibration curve of 3 prediction models within 3 years after diagnosis. A: The Kaplan-Meier curve of venous, arterial and both venous and arterial thrombosis. B: The calibration curves for venous thrombosis. C: The calibration curves for arterial thrombosis. D: The calibration curves for both venous and arterial thrombosis.ConclusionThe ability of aGAPSS, Padua score and Caprini score to predict thrombosis in APS patients is relatively poor. Construction of a new prediction model specifically for APS patients is required to help with early prevention and treatment.References[1]Sciascia, S., et al., GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford), 2013. 52(8): p. 1397-403.Disclosure of InterestsNone declared
Collapse
|
84
|
Deng Y, Wang W, Zheng Q, Feng Y, Zou Y, Dong H, Tan Z, Zeng X, Zhao Y, Peng D, Yang X, Sun A. Menopausal hormone therapy: what are the problems in the perception of Chinese physicians? Climacteric 2022; 25:413-420. [PMID: 35438051 DOI: 10.1080/13697137.2022.2058391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE This study aimed to investigate Chinese physicians' perception and attitudes toward menopausal hormone therapy (MHT). METHODS This nationwide online survey was conducted in China. Physicians registered in the WeChat groups of the Gynecological Endocrinology Committee of China's Maternal and Child Health Care Association received a message invitation to complete this anonymous online survey from April 2020 to July 2020. Physicians' knowledge of and attitudes toward MHT were surveyed. RESULTS In total, 4672 questionnaires were submitted; only completed questionnaires could be submitted. The message was sent to 6021 doctors, so the response rate was 77.6%. Overall, 77.9-92.9% of physicians knew the common indications and contraindications to MHT. Additionally, 90.6%, 85.4%, 80.7% and 37.5% of physicians thought that MHT would increase the risk of venous thrombosis, breast cancer, endometrial cancer and weight gain, respectively. In total, 58.1% of the physicians mistakenly believed that a sex hormone test was one of the necessary examinations to reassess MHT prescription during follow-up visits. We found that 68.5% of physicians would consider using MHT themselves or recommend MHT to their partners in the future, and 11.4% were currently using MHT. CONCLUSIONS Most Chinese physicians have basic knowledge of MHT. Their misunderstandings about MHT mainly centered on the risks of endometrial cancer, weight gain and the necessary examinations during follow-up visits. These misunderstandings need to be clarified in future professional training programs.
Collapse
|
85
|
Ablikim M, Achasov MN, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen DY, Chen G, Chen HS, Chen ML, Chen SJ, Chen XR, Chen YB, Chen ZJ, Cheng WS, Cibinetto G, Cossio F, Cui XF, Dai HL, Dai JP, Dai XC, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fritsch M, Fu CD, Gao Y, Gao Y, Gao YG, Garzia I, Ge PT, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Guan CY, Guo AQ, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Holtmann T, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Andersson WI, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jiang HB, Jiang XS, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth MG, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JL, Li JQ, Li JS, Li K, Li LK, Li L, Li PR, Li SY, Li WD, Li WG, Li XH, Li XL, Li X, Li ZY, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu PL, Liu Q, Liu Q, Liu SB, Liu T, Liu T, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JD, Lu JG, Lu XL, Lu Y, Lu YP, Luo CL, Luo MX, Luo PW, Luo T, Luo XL, Lyu XR, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XX, Ma XY, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Patteri P, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Plura S, Pogodin S, Poling R, Prasad V, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Ravindran K, Redmer CF, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan W, Shan XY, Shangguan JF, Shao M, Shen CP, Shen HF, Shen XY, Shi HC, Shi RS, Shi X, Shi XD, Song JJ, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Sui FF, Sun GX, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Teng JX, Thoren V, Tian WH, Tian YT, Uman I, Wang B, Wang CW, Wang DY, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YQ, Wang YY, Wang Z, Wang ZY, Wang Z, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Z, Xia L, Xiao H, Xiao SY, Xiao ZJ, Xie XH, Xie YG, Xie YH, Xing TY, Xu CJ, Xu GF, Xu QJ, Xu W, Xu XP, Xu YC, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HX, Yang L, Yang SL, Yang YX, Yang Y, Yang Z, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yuan CZ, Yuan L, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng X, Zeng Y, Zhang AQ, Zhang BX, Zhang G, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang S, Zhang SF, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhou LP, Zhou Q, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu SH, Zhu TJ, Zhu WJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Observation of the Singly Cabibbo Suppressed Decay Λ_{c}^{+}→nπ^{+}. PHYSICAL REVIEW LETTERS 2022; 128:142001. [PMID: 35476477 DOI: 10.1103/physrevlett.128.142001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 02/05/2022] [Accepted: 03/01/2022] [Indexed: 06/14/2023]
Abstract
The singly Cabibbo-suppressed decay Λ_{c}^{+}→nπ^{+} is observed for the first time with a statistical significance of 7.3σ by using 3.9 fb^{-1} of e^{+}e^{-} collision data collected at center-of-mass energies between 4.612 and 4.699 GeV with the BESIII detector at BEPCII. The branching fraction of Λ_{c}^{+}→nπ^{+} is measured to be (6.6±1.2_{stat}±0.4_{syst})×10^{-4}. By taking the upper limit of branching fractions of Λ_{c}^{+}→pπ^{0} from the Belle experiment, the ratio of branching fractions between Λ_{c}^{+}→nπ^{+} and Λ_{c}^{+}→pπ^{0} is calculated to be larger than 7.2 at the 90% confidence level, which disagrees with most predictions of the available phenomenological models. In addition, the branching fractions of the Cabibbo-favored decays Λ_{c}^{+}→Λπ^{+} and Λ_{c}^{+}→Σ^{0}π^{+} are measured to be (1.31±0.08_{stat}±0.05_{syst})×10^{-2} and (1.22±0.08_{stat}±0.07_{syst})×10^{-2}, respectively, which are consistent with previous results.
Collapse
|
86
|
Han Y, Han K, Zhang Y, Zeng X. Correction to: Serum 25-hydroxyvitamin D might be negatively associated with hyperuricemia in U.S. adults: an analysis of the National Health and Nutrition Examination Survey 2007-2014. J Endocrinol Invest 2022; 45:907. [PMID: 35113405 PMCID: PMC9172642 DOI: 10.1007/s40618-021-01734-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
87
|
Han Y, Han K, Zhang Y, Zeng X. Serum 25-hydroxyvitamin D might be negatively associated with hyperuricemia in U.S. adults: an analysis of the National Health and Nutrition Examination Survey 2007-2014. J Endocrinol Invest 2022; 45:719-729. [PMID: 34435335 PMCID: PMC8918159 DOI: 10.1007/s40618-021-01637-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 07/11/2021] [Indexed: 12/16/2022]
Abstract
PURPOSE The results of previous studies on the relationship between serum 25-hydroxyvitamin D [25(OH)D] and hyperuricemia are controversial. We hypothesized that serum 25(OH)D concentrations of U.S. adults would negatively correlate with the risk of hyperuricemia. METHOD Data came from the National Health and Nutrition Examination Survey 2007-2014 were used, after excluding those who met at least one of the exclusion criteria, a total of 9096 male individuals and 9500 female individuals aged 18 years or older were included. Binary logistic regression analysis and restricted cubic spline with fully adjusted confounding factors were applied to evaluate the association between serum 25(OH)D and hyperuricemia. We further performed stratified analysis and sensitivity analysis to minimize the influence of gender, metabolic syndrome, obesity and renal dysfunction on the above association. RESULTS We found a negative correlation between serum 25(OH)D and hyperuricemia. In the binary logistic regression analysis, compared with the highest serum 25(OH)D quartile [Q4: 25(OH)D > 77.10 nmol/L] group, the odds ratios (95% confidence intervals) in the lowest quartile [Q1: 25(OH)D ≤ 43.20 nmol/L] was 1.46 (1.22-1.75) in the fully adjusted model. Restricted cubic spline analysis showed L-shaped and non-linear relationships between 25(OH)D and hyperuricemia. In sensitivity analysis, after restricting to participants without significant renal dysfunction and obesity, the above association remained significant. After restricting to participants who were diagnosed as metabolic syndrome, above association remained significant in the fully adjusted model. In stratified analysis by gender, the association remained significant among males and females. CONCLUSIONS Serum 25(OH)D might be inversely associated with hyperuricemia in general U.S. adults. From our study, for people with unexplained hyperuricemia, screening for serum Vitamin D concentration might be necessary.
Collapse
|
88
|
Wei X, Min Y, Feng Y, He D, Zeng X, Huang Y, Fan S, Chen H, Chen J, Xiang K, Luo H, Yin G, Hu D. Development and validation of an individualized nomogram for predicting the high-volume (> 5) central lymph node metastasis in papillary thyroid microcarcinoma. J Endocrinol Invest 2022; 45:507-515. [PMID: 34491546 DOI: 10.1007/s40618-021-01675-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2021] [Accepted: 09/03/2021] [Indexed: 01/30/2023]
Abstract
PURPOSE Papillary thyroid microcarcinoma (PTMC) frequently presents a favorable clinical outcome, while aggressive invasiveness can also be found in some of this population. Identifying the risk clinical factors of high-volume (> 5) central lymph node metastasis (CLNM) in PTMC patients could help oncologists make a better-individualized clinical decision. METHODS We retrospectively reviewed the clinical characteristics of adult patients with PTC in the Surveillance, Epidemiology, and End Results (SEER) database between Jan 2010 and Dec 2015 and in one medical center affiliated to Chongqing Medical University between Jan 2018 and Oct 2020. Univariate and multivariate logistic regression analyses were used to determine the risk factors for high volume of CLNM in PTMC patients. RESULTS The male gender (OR = 2.02, 95% CI 1.46-2.81), larger tumor size (> 5 mm, OR = 1.64, 95% CI 1.13-2.38), multifocality (OR = 1.87, 95% CI 1.40-2.51), and extrathyroidal invasion (OR = 3.67; 95% CI 2.64-5.10) were independent risk factors in promoting high-volume of CLNM in PTMC patients. By contrast, elderly age (≥ 55 years) at diagnosis (OR = 0.57, 95% CI 0.40-0.81) and PTMC-follicular variate (OR = 0.60, 95% CI 0.42-0.87) were determined as the protective factors. Based on these indicators, a nomogram was further constructed with a good concordance index (C-index) of 0.702, supported by an external validating cohort with a promising C-index of 0.811. CONCLUSION A nomogram was successfully established and validated with six clinical indicators. This model could help surgeons to make a better-individualized clinical decision on the management of PTMC patients, especially in terms of whether prophylactic central lymph node dissection and postoperative radiotherapy should be warranted.
Collapse
|
89
|
Luo D, Liu D, Rao C, Shi S, Zeng X, Liu S, Jiang H, Liu L, Zhang Z, Lu X. Raised SPINK1 levels play a role in angiogenesis and the transendothelial migration of ALL cells. Sci Rep 2022; 12:2999. [PMID: 35194087 PMCID: PMC8864021 DOI: 10.1038/s41598-022-06946-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Accepted: 02/09/2022] [Indexed: 11/23/2022] Open
Abstract
The present study was designed to assess whether raised Serine protease inhibitor Kazal type 1 (SPINK1) expressions modulates angiogenesis. Human umbilical vein endothelial cells (HUVECs) exposed to SPINK1 were noted to exhibit raised expressions of interleukin-8 (IL-8) as well as VCAM-1 and ICAM-1 cell adhesion molecules in a dose-dependent manner. In co-culture system of HUVECs and Acute lymphoblastic leukemia (ALL) cells, SPINK1 exposure also resulted in enhanced endothelial cell motility and ALL cells trans-endothelial migration. High concentrations of SPINK1 caused in vitro cellular reorganization into tubes in Matrigel-cultured HUVECs and induced in vivo vascularization and brain infiltration of NOD/SCID ALL model mice. The further transcriptomic analysis indicated that SPINK1 treatment altered several biological processes of endothelial cells and led to activation of the MAPK pathway. This study is the first to determine the neovascularization effects of raised SPINK1.
Collapse
|
90
|
Yang G, Zhao T, Lu S, Weng J, Zeng X. T1121G Point Mutation in the Mitochondrial Gene COX1 Suppresses a Null Mutation in ATP23 Required for the Assembly of Yeast Mitochondrial ATP Synthase. Int J Mol Sci 2022; 23:ijms23042327. [PMID: 35216443 PMCID: PMC8877559 DOI: 10.3390/ijms23042327] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 02/10/2022] [Accepted: 02/16/2022] [Indexed: 02/04/2023] Open
Abstract
Nuclear-encoded Atp23 was previously shown to have dual functions, including processing the yeast Atp6 precursor and assisting the assembly of yeast mitochondrial ATP synthase. However, it remains unknown whether there are genes functionally complementary to ATP23 to rescue atp23 null mutant. In the present paper, we screen and characterize three revertants of atp23 null mutant and reveal a T1121G point mutation in the mitochondrial gene COX1 coding sequence, which leads to Val374Gly mutation in Cox1, the suppressor in the revertants. This was verified further by the partial restoration of mitochondrial ATP synthase assembly in atp23 null mutant transformed with exogenous hybrid COX1 T1121G mutant plasmid. The predicted tertiary structure of the Cox1 p.Val374Gly mutation showed no obvious difference from wild-type Cox1. By further chase labeling with isotope [35S]-methionine, we found that the stability of Atp6 of ATP synthase increased in the revertants compared with the atp23 null mutant. Taking all the data together, we revealed that the T1121G point mutation of mitochondrial gene COX1 could partially restore the unassembly of mitochondrial ATP synthase in atp23 null mutant by increasing the stability of Atp6. Therefore, this study uncovers a gene that is partially functionally complementary to ATP23 to rescue ATP23 deficiency, broadening our understanding of the relationship between yeast the cytochrome c oxidase complex and mitochondrial ATP synthase complex.
Collapse
|
91
|
Zeng X, Jiang J, Wang F, Liu W, Zhang S, Du J, Yang C. Rice OsClo5, a caleosin protein, negatively regulates cold tolerance through the jasmonate signalling pathway. PLANT BIOLOGY (STUTTGART, GERMANY) 2022; 24:52-61. [PMID: 34694678 DOI: 10.1111/plb.13350] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 09/24/2021] [Indexed: 06/13/2023]
Abstract
Caleosin is a lipid droplet-binding protein involved in maintenance of the lipid droplet structure and in signal transduction. However, the role of caleosin proteins in stress resistance is limited. Here, we report data for a rice caleosin protein gene, OsClo5, involved in cold stress tolerance via influence and regulation of the JA signalling pathway. Overexpression lines and RNAi lines of OsClo5 were subjected to cold stress and recovery to measure electrolyte leakage and survival rate. Changes were also detected in the genome-wide transcriptome of OsClo5 overexpressed plants. OsClo5 is located mainly in lipid droplets and expressed in all tissues tested. Its expression was upregulated by various stress conditions when subjected to cold treatment. Overexpression of OsClo5 decreased cold tolerance, and RNAi lines of OsClo5 had higher survival than WT seedlings. OsClo5 inhibited one jasmonate biosynthetic gene and several jasmonate ZIM domain (JAZ) genes, which were upregulated in response to cold stress. OsClo5 is a constitutively expressed caleosin protein that regulates plant cold resistance through inhibition of jasmonate signalling and JA synthesis.
Collapse
|
92
|
Zeng X, Chunyang L, Hao Y, Wang D, Fan F, Wang C, Deng Z, Guo H, Wang Z. Pregnancy diagnosis and fetal monitoring in Yangtze finless porpoises. ENDANGER SPECIES RES 2022. [DOI: 10.3354/esr01179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
93
|
Yang T, Zhou W, Xu W, Ran L, Yan Y, Lu L, Mi J, Zeng X, Cao Y. Modulation of gut microbiota and hypoglycemic/hypolipidemic activity of flavonoids from the fruits of Lycium barbarum on high-fat diet/streptozotocin-induced type 2 diabetic mice. Food Funct 2022; 13:11169-11184. [DOI: 10.1039/d2fo01268e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Lycium barbarum has been used as a traditional medicinal and edible plant in China. The fruits of L. barbarum, rich in flavonoids with large exploration potentiality, are associated with antioxidant...
Collapse
|
94
|
Chen R, Du S, Yao Y, Zhang L, Luo J, Shen Y, Xu Z, Zeng X, Zhang L, Liu M, Yin C, Tang B, Tan J, Xu X, Liu JY. A Novel SPAST Mutation Results in Spastin Accumulation and Defects in Microtubule Dynamics. Mov Disord 2021; 37:598-607. [PMID: 34927746 PMCID: PMC9300132 DOI: 10.1002/mds.28885] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 11/24/2021] [Accepted: 11/27/2021] [Indexed: 11/25/2022] Open
Abstract
Background Haploinsufficiency is widely accepted as the pathogenic mechanism of spastic paraplegia type 4 (SPG4). However, there are some cases that cannot be explained by reduced function of the spastin protein encoded by SPAST. Objectives To identify the causative gene of autosomal dominant hereditary spastic paraplegia in three large Chinese families and explore the pathological mechanism of a spastin variant. Methods Three large Chinese hereditary spastic paraplegia families with a total of 247 individuals (67 patients) were investigated, of whom 59 members were recruited to the study. Genetic testing was performed to identify the causative gene. Western blotting and immunofluorescence were used to analyze the effects of the mutant proteins in vitro. Results In the three hereditary spastic paraplegia families, of whom three index cases were misdiagnosed as other types of neurological diseases, a novel c.985dupA (p.Met329Asnfs*3) variant in SPAST was identified and was shown to cosegregate with the phenotype in the three families. The c.985dupA mutation produced two truncated mutants (mutant M1 and M87 isoforms) that accumulated to a higher level than their wild‐type counterparts. Furthermore, the mutant M1 isoform heavily decorated the microtubules and rendered them resistant to depolymerization. In contrast, the mutant M87 isoform was diffusely localized in both the nucleus and the cytoplasm, could not decorate microtubules, and was not able to promote microtubule disassembly. Conclusions SPAST mutations leading to premature stop codons do not always act through haploinsufficiency. The truncated spastin may damage the corticospinal tracts through an isoform‐specific toxic effect.
Collapse
|
95
|
Zhang B, Xu N, Chen J, Zhang S, Huang X, Shen M, Zeng X. Treatment and outcome in deficiency of adenosine deaminase 2: a literature review. J Investig Allergol Clin Immunol 2021; 32:13-22. [PMID: 34489224 DOI: 10.18176/jiaci.0748] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
OBJECTIVES Deficiency of adenosine deaminase 2 (DADA2) is a rare disease with varying phenotypes and disease outcomes. We aimed to summarize the treatments of DADA2 and to explore the factors associated with disease outcome. MATERIAL AND METHODS A systemic literature review of DADA2 was conducted. Cases were included if they had documented detailed genotypes, phenotypes, treatment protocols and outcomes. Patients were categorized into uncontrolled and controlled groups. Factors associated with disease outcome were analyzed with logistic regression models. RESULTS A total of 242 DADA2 patients with treatment protocols and responses were included, 17 of whom required no treatment. The general effective rate of TNFi was 78.6% (103/131). Hematological abnormalities and increased acute phase reactants are independently associated with TNFi effectiveness, OR=0.21 (95%CI 0.07-0.661, p=0.007) and 9.62 (95%CI 2.31-40.00, p=0.002), respectively. Among those 225 patients requiring active treatment, 157 (69.8%) patients were in the controlled group, and 68(30.2%) in the uncontrolled group. Neither age of disease onset nor genotype was associated with disease outcome. Increased acute phase reactants (APRs), constitutional symptoms, neurological symptoms, and treatment with TNF inhibitors (TNFi) were independently associated with disease control, while recurrent infections and severe vascular events were the main causes of mortality (10/21 and 6/21, respectively). CONCLUSIONS In patients requiring treatment, symptoms of systemic inflammation and vasculitis and TNFi treatment are associated with disease control; while recurrent infections and severe vascular events should be treated intensively as they are the main causes of death. Hematological abnormalities should be monitored as it would decrease TNFi effectiveness.
Collapse
|
96
|
Xiong J, Yang J, Li W, Xiong H, Liu G, Wu F, Fan N, Zeng X, Huang F, Yang L, Tu X, Shi C, Yi B, Ye J, Li P, Tang C, Huang J, Hou P, Zang W, Tan S. 1411P A prospective, multicenter, real-world study of apatinib in the treatment of gastric cancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
97
|
Ablikim M, Achasov M, Adlarson P, Ahmed S, Albrecht M, Aliberti R, Amoroso A, An M, An Q, Bai X, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere R, Cai H, Cai X, Calcaterra A, Cao G, Cao N, Cetin S, Chang J, Chang W, Chelkov G, Chen D, Chen G, Chen H, Chen M, Chen S, Chen X, Chen Y, Chen Z, Cheng W, Cibinetto G, Cossio F, Cui X, Dai H, Dai X, Dbeyssi A, de Boer R, Dedovich D, Deng Z, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong C, Dong J, Dong L, Dong M, Dong X, Du S, Fan Y, Fang J, Fang S, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng C, Feng J, Fritsch M, Fu C, Gao Y, Gao Y, Gao Y, Gao Y, Garzia I, Ge P, Geng C, Gersabeck E, Gilman A, Goetzen K, Gong L, Gong W, Gradl W, Greco M, Gu L, Gu M, Gu S, Gu Y, Guan C, Guo A, Guo L, Guo R, Guo Y, Guskov A, Han T, Han W, Hao X, Harris F, Hüsken N, He K, Heinsius F, Heinz C, Held T, Heng Y, Herold C, Himmelreich M, Holtmann T, Hou G, Hou Y, Hou Z, Hu H, Hu J, Hu T, Hu Y, Huang G, Huang L, Huang X, Huang Y, Huang Z, Hussain T, Andersson WI, Imoehl W, Irshad M, Jaeger S, Janchiv S, Ji Q, Ji Q, Ji X, Ji X, Ji Y, Jiang H, Jiang X, Jiao J, Jiao Z, Jin S, Jin Y, Jing M, Johansson T, Kalantar-Nayestanaki N, Kang X, Kappert R, Kavatsyuk M, Ke B, Keshk I, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu O, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kurth M, Kühn W, Lane J, Lange J, Larin P, Lavania A, Lavezzi L, Lei Z, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li C, Li D, Li F, Li G, Li H, Li H, Li H, Li H, Li J, Li J, Li J, Li K, Li L, Li L, Li P, Li S, Li W, Li W, Li X, Li X, Li X, Li Z, Liang H, Liang H, Liang H, Liang Y, Liang Y, Liao G, Liao L, Libby J, Lin C, Liu B, Liu C, Liu D, Liu F, Liu F, Liu F, Liu H, Liu H, Liu H, Liu H, Liu J, Liu J, Liu J, Liu K, Liu K, Liu L, Liu M, Liu P, Liu Q, Liu Q, Liu S, Liu S, Liu T, Liu W, Liu X, Liu Y, Liu Y, Liu Z, Liu Z, Lou X, Lu F, Lu H, Lu J, Lu J, Lu X, Lu Y, Lu Y, Luo C, Luo M, Luo P, Luo T, Luo X, Lyu X, Ma F, Ma H, Ma L, Ma M, Ma Q, Ma R, Ma R, Ma X, Ma X, Maas F, Maggiora M, Maldaner S, Malde S, Malik Q, Mangoni A, Mao Y, Mao Z, Marcello S, Meng Z, Messchendorp J, Mezzadri G, Min T, Mitchell R, Mo X, Mo Y, Muchnoi N, Muramatsu H, Nakhoul S, Nefedov Y, Nerling F, Nikolaev I, Ning Z, Nisar S, Olsen S, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pelizaeus M, Peng H, Peters K, Pettersson J, Ping J, Ping R, Poling R, Prasad V, Qi H, Qi H, Qi K, Qi M, Qi T, Qian S, Qian W, Qian Z, Qiao C, Qin L, Qin X, Qin X, Qin Z, Qiu J, Qu S, Rashid K, Ravindran K, Redmer C, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Rump M, Sang H, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan D, Shan W, Shan X, Shangguan J, Shao M, Shen C, Shen H, Shen P, Shen X, Shi H, Shi R, Shi X, Shi X, Song J, Song W, Song Y, Sosio S, Spataro S, Su K, Su P, Sui F, Sun G, Sun H, Sun J, Sun L, Sun S, Sun T, Sun W, Sun W, Sun X, Sun Y, Sun Y, Sun Y, Sun Z, Tan Y, Tan Y, Tang C, Tang G, Tang J, Teng J, Thoren V, Tian W, Tian Y, Uman I, Wang B, Wang C, Wang D, Wang H, Wang H, Wang K, Wang L, Wang M, Wang M, Wang M, Wang W, Wang W, Wang W, Wang X, Wang X, Wang X, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Y, Wang Z, Wang Z, Wang Z, Wang Z, Wei D, Weidner F, Wen S, White D, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu J, Wu L, Wu L, Wu X, Wu Z, Xia L, Xiao H, Xiao S, Xiao Z, Xie X, Xie Y, Xie Y, Xing T, Xu G, Xu Q, Xu W, Xu X, Xu Y, Yan F, Yan L, Yan W, Yan W, Yan X, Yang H, Yang H, Yang L, Yang S, Yang Y, Yang Y, Yang Z, Ye M, Ye M, Yin J, You Z, Yu B, Yu C, Yu G, Yu J, Yu T, Yuan C, Yuan L, Yuan X, Yuan Y, Yuan Z, Yue C, Yuncu A, Zafar A, Zeng X, Zeng Y, Zhang A, Zhang B, Zhang G, Zhang H, Zhang H, Zhang H, Zhang H, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang J, Zhang L, Zhang L, Zhang L, Zhang S, Zhang S, Zhang S, Zhang X, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Y, Zhang Z, Zhang Z, Zhao G, Zhao J, Zhao J, Zhao J, Zhao L, Zhao L, Zhao M, Zhao Q, Zhao S, Zhao Y, Zhao Y, Zhao Z, Zhemchugov A, Zheng B, Zheng J, Zheng Y, Zheng Y, Zhong B, Zhong C, Zhou L, Zhou Q, Zhou X, Zhou X, Zhou X, Zhou X, Zhu A, Zhu J, Zhu K, Zhu K, Zhu S, Zhu T, Zhu W, Zhu W, Zhu Y, Zhu Z, Zou B, Zou J. Study of the decay
D+→K*(892)+KS0
in
D+→K+KS0π0. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.012006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
98
|
Zeng X, Zhao D, Radominski S, Keiserman M, Lee CK, Martin N, Meerwein S, Sui Y, Park W. AB0260 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA, BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: RESULTS AT 64 WEEKS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Upadacitinib (UPA), an oral Janus kinase inhibitor, in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), showed significant improvements in clinical and functional measures compared with placebo (PBO) up to 12 weeks (wks), in patients (pts) from China, Brazil, and South Korea with rheumatoid arthritis (RA) and prior inadequate response to csDMARDs (csDMARD-IR).1Objectives:To assess the efficacy and safety of UPA up to 64 wks (long-term extension; LTE) in csDMARD-IR pts with RA from China, Brazil, and South Korea.Methods:Pts were randomized to 12 wks of blinded treatment with UPA 15 mg once daily (QD) or PBO, in combination with csDMARDs. From Wk 12 onward, pts could continue to receive open-label UPA 15 mg QD. Efficacy endpoints were analyzed by original randomized treatment group sequences over 64 wks and included American College of Rheumatology (ACR) responses, and key remission and low disease activity measures. Non-responder imputation was used to handle missing data for binary endpoints. Treatment-emergent adverse events (TEAEs) per 100 patient-years (PY) were summarized for pts receiving ≥1 dose of UPA from baseline through to Wk 64.Results:Of 338 randomized pts who received ≥1 dose of study drug, 310 (91.7%) entered the LTE and 275 (81.4%) completed 64 wks of treatment. Among those initially randomized to UPA, the proportion of pts achieving 20%/50%/70% improvement in ACR criteria, and key remission and low disease activity measures increased over 64 wks of treatment (Figure 1). Improvements from baseline in the Health Assessment Questionnaire-Disability Index and pts’ assessment of pain were observed over 64 wks of UPA treatment (data not shown). By Wk 64, efficacy results for pts who switched from PBO to UPA at Wk 12 followed a similar trajectory to those originally randomized to UPA.The observed rate of serious infections was 8.1 events/100 PY. Herpes zoster events were mostly non-serious, involving only 1 or 2 dermatomes. Most cases of hepatic disorders were Grade 1 or 2 hepatic transaminase elevations. There was 1 case of venous thromboembolic event (VTE; concurrent pulmonary embolism and deep vein thrombosis [DVT] in a patient with a history of DVT) and 3 cases of malignancy. Adjudicated major adverse cardiovascular events (Table 1) occurred in 2 pts (1 with non-fatal myocardial infarction and 1 with non-fatal stroke) who had underlying risk factors for cardiovascular disease. There were no deaths, active tuberculosis, or renal dysfunction.Conclusion:UPA 15 mg was effective in treating the signs and symptoms of RA and in improving physical function over 64 wks with no new safety signals1 in csDMARD-IR pts with RA from China, Brazil, and South Korea.References:[1]Zeng A, et al. Ann Rheum Dis 2020;79(Suppl 1):1016 [abstract SAT0160]Table 1.TEAEs at Wk 64Event (E/100 PY)UPA 15 mg(n=322; PY=334.5)Any AE421.5 (399.8–444.1) Serious AE19.1 (14.7–24.4) AE leading to discontinuation of study drug9.0 (6.1–12.8) Deathsa0AEs of special interest Serious infection8.1 (5.3–11.7) Opportunistic infection0.9 (0.2–2.6) Herpes zoster9.0 (6.1–12.8) Hepatic disorder42.2 (35.5–49.7) Gastrointestinal perforation (adjudicated)0.3 (0.0–1.7) Any malignancy (excluding NMSC)0.6 (0.1–2.2) NMSC0.3 (0.0–1.7) MACE (adjudicated)b0.6 (0.1–2.2) VTE (adjudicated)c0.3 (0.0–1.7) Anemia11.1 (7.8–15.2) Neutropenia11.7 (8.3–15.9) Lymphopenia7.8 (5.1–11.4) CPK elevation11.1 (7.8–15.2)aIncluding non-treatment-emergent deaths. bDefined as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. cIncluding DVT and pulmonary embolism.AE, adverse event; CPK, creatine phosphokinase; E, events; MACE, major adverse cardiovascular event; NMSC, non-melanoma skin cancerAcknowledgements:AbbVie funded this study; contributed to its design; participated in data collection, analysis, and interpretation of the data; and in the writing, review, and approval of the abstract. No honoraria or payments were made for authorship. Yanna Song, PhD, of AbbVie provided statistical support. Medical writing support was provided by Laura Chalmers, PhD, of 2 the Nth (Cheshire, UK), and was funded by AbbVie.Disclosure of Interests:Xiaofeng Zeng: None declared, Dongbao Zhao: None declared, Sebastiao Radominski: None declared, MAURO KEISERMAN: None declared, Chang-Keun Lee: None declared, Naomi Martin Employee of: AbbVie employee and may own stock or options, Sebastian Meerwein Employee of: AbbVie employee and may own stock or options, Yunxia Sui Employee of: AbbVie employee and may own stock or options, Won Park: None declared
Collapse
|
99
|
You H, Li M, Zhao JL, Wu L, Duan X, Luo H, Zhao C, Zhan F, Wu Z, Li H, Yang M, Xu J, Wei W, Wang Y, Shi J, Qu J, Wang Q, Leng X, Tian X, Zhao Y, Zeng X. POS0754 DEVELOPMENT OF A RISK PREDICTION MODEL FOR VENOUS THROMBOEMBOLISM IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: THE SLE-VTE SCORE. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Patients with systemic lupus erythematosus (SLE) have a substantially increased risk of venous thromboembolism (VTE). An individual VTE risk assessment is important to ensure that all patients are assessed and given adequate thromboprophylaxis.Objectives:We conducted this study to develop a risk score for VTE in patients with SLE.Methods:Patients with SLE who participated in the Chinese SLE Treatment and Research group were enrolled in this study. Patient baseline information and clinical laboratory indicators were obtained, and VTE events were recorded every 3-6 months during follow-up visits. The risk prediction model was created and internally validated using the bootstrap methods, and a scoring system was established (Figure 1).Figure 1.Flow chart of study design.Results:Out of 4,502 patients included in this study, 135 had a VTE event. After univariate analysis and Lasso regression, the following 11 variables were identified and included in the risk prediction model: male sex, age, BMI ≥25 kg/m2, hyperlipidemia, hypoalbuminemia, hsCRP>3 mg/L, renal involvement, nervous system involvement, anti-β2-glycoprotein I antibody positivity, lupus anticoagulant positivity, and no use of hydroxychloroquine. The AUC for the SLE-VTE score (Table 1) was 0.947 (95% CI, 0.9249-0.9694). The SLE-VTE score’s sensitivity and specificity with the optimal cutoff value of 13 were 0.919 and 0.881, respectively. The SLE-VTE score was superior to the GAPSS system in predicting the risk of VTE in patients with SLE (AUC= 0.947 vs. 0.680, P< 0.001; integrated discrimination improvement (IDI)= 0.6652, P< 0.001; net reclassification improvement (NRI)= 0.6652, P< 0.001).Table 1.Final multivariable analysis for venous thromboembolism risk in patients with SLE β coefficientsOdds ratio* (95% CI)P-valuePoints in scoring systemMale0.6211.86(0.953-3.503)0.0612Age at study entry(≥50)0.8372.308(1.339-3.915)0.0023BMI02(kg/m20.7922.209(1.333-3.627)0.0023Hyperlipemia0.8382.313(1.246-4.166)0.0063Hypoalbuminemia2.1638.697(5.185-14.794)< 0.0017hsCRP>3 mg/L1.4524.272(2.618-6.968)< 0.0015Anti β2GPI1.0132.754(1.543-4.853)0.0013LA1.5594.752(2.799-8.072)< 0.0015Nervous system2.38210.832(6.163-18.998)< 0.0018Lupus nephritis0.8352.305(1.414-3.756)0.0013No use of hydroxychloroquine1.7715.876(3.722-9.401)< 0.0016BMI: body mass index; hsCRP: Hypersensitive c-reactive protein; ACL: anticardiolipin, antiβ2GPI: anti-β2-glycoprotein I, LA: lupus anticoagulantm;Values in bold are statistically significant at p <0.05.Conclusion:Various factors are related to the occurrence of VTE in patients with SLE. The proposed SLE-VTE risk score can accurately predict the risk of VTE and help identify SLE patients with a high risk of VTE who may benefit from thromboprophylaxis.References:[1]Ramirez GA, Efthymiou M, Isenberg DA, Cohen H. Under crossfire: thromboembolic risk in systemic lupus erythematosus. Rheumatology. 2018;58:940-952.[2]Chung WS, Lin CL, Chang SN, Lu CC, Kao CH. Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study. J Thromb Haemost. 2014;12:452-458.[3]Liew NC, Alemany GV, Angchaisuksiri P, et al. Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. Int Angiol. 2017;36:1.[4]Savino S, Giovanni S, Veronica M, Dario R, Khamashta MA, Laura BM. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology. 2013:8.[5]Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543-603.[6]Moghadamyeghaneh Z, Hanna MH, Carmichael JC, Nguyen NT, Stamos MJ. A Nationwide Analysis of Postoperative Deep Vein Thrombosis and Pulmonary Embolism in Colon and Rectal Surgery. J Gastrointest Surg. 2014;18:2169-2177.Disclosure of Interests:None declared
Collapse
|
100
|
Qi W, Zhao JL, Tian X, LI M, Zeng X. OP0290 CLINICAL CHARACTERISTICS AND PROGNOSIS OF ANTIPHOSPHOLIPID SYNDROME PATIENTS BASED ON CLUSTER ANALYSIS: A 10-YEAR COHORT STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:APS is an autoimmune disease characterized by persistent antiphospholipid antibodies (aPLs) positivity, leading to thrombotic events or pregnancy morbidity. High-risk aPLs profiles included positive lupus anticoagulant (LA) and multiple aPLs positivity1. Association was also found between aPLs and a variety of manifestations beyond thrombosis, referred to “non-criteria manifestations” (i.e. thrombocytopenia, hemolytic anemia, heart valve disease and aPL-related nephropathy)2, of which the role in APS risk stratification is poorly understood. The manifestation spectrum of APS is wide, ranging from asymptomatic aPLs positivity to life-threatening catastrophic APS, and patients other than confirmed APS also need proper management. Therefore, a risk stratification integrating demographic data, aPL-related manifestations, aPLs profiles, coexisting cardiovascular risk factors and SLE is needed for management guidance and prognosis assessment.Objectives:Using cluster analysis, to identify phenotypes among aPL-positive patients and assess the prognosis of each phenotype.Methods:This is a single-center, prospective cohort study of aPL-positive patients who presented to Peking Union Medical College Hospital from 2004 to 2020. Demographic characteristics, aPL-related manifestations, cardiovascular risk factors, antibodies profile and follow-up data were recorded. The primary end point was defined as a combination of newly onset arterial thrombosis (AT) or deep venous thrombosis (DVT), major bleeding events, non-criteria manifestations and all-cause death. Hierarchical cluster analysis with the Euclidean distance and the Ward method was applied to identify clusters of patients and variables separately. Multiple comparison and Kaplan-Meier survival analysis were performed among clusters.Results:Four clusters among 383 patients (70.2% female; mean age 37.7 years) were identified (Figure 1A). Cluster 1 (n=138): female patients with SLE, non-criteria manifestations, triple aPLs positivity, high AT rate and moderate DVT rate. Cluster 2 (n=112): male patients with obesity, smoking history, hypertension, hyperhomocysteinemia, triple aPLs positivity and the highest rate of AT and DVT. Cluster 3 (n=83): female patients with the highest pregnancy morbidity rate and the lowest thrombosis rate. Cluster 4 (n=50): 62% male patients with isolated LA positivity, high AT rate and moderate DVT rate. Four clusters of variables were also identified (Figure 1A). From Kaplan-Meier survival analysis, 1-, 5- and 10-year event-free survival rates were 92.6%, 79.8% and 66.8%, respectively. Cluster 3 showed lowest incidence of primary endpoint (Figure 1B), while Cluster 1 and 2 showed higher newly-onset AT risk compared with other clusters (P=0.028 for 2 vs 3 and P=0.049 for 2 vs 4).Figure 1.Conclusion:We identified 4 clinical phenotypes of aPL-positive patients. APS secondary to SLE was always aggregated with non-criteria manifestations. Clinicians should be alert to the possibility of SLE in aPL-positive patients with coexisting non-criteria manifestations, for whom immunosuppressive therapy besides anticoagulation may be necessary. Cluster 4 represented patients with isolated LA positivity and shared similar prognosis with secondary APS and male patients, which confirmed that LA represented a high-risk antibody spectrum. Additionally, cardiovascular risk factors (i.e. male, smoking history and obesity) played an important role in thrombosis events, and led to poor prognosis. Therefore, more attention should be paid to male patients, and the screening and management of cardiovascular risk factors should not be ignored.References:[1]Tektonidou MG, Andreoli L, Limper M et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296–304.[2]Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.Disclosure of Interests:None declared.
Collapse
|